Sanofi makes headway with Lantus follow-up U300
This article was originally published in Scrip
Executive Summary
Sanofi has reported more key data that will underpin its efforts to shift sales from the long-acting insulin product Lantus (insulin glargine), to its new improved version, U300, and fight off competition from Novo Nordisk's similar offering Tresiba (insulin degludec).